{
  "zip": "V7X 1J1",
  "sector": "Healthcare",
  "fullTimeEmployees": 7,
  "longBusinessSummary": "NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.",
  "city": "Vancouver",
  "phone": "604 488 5421",
  "state": "BC",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.nervgen.com",
  "maxAge": 1,
  "address1": "Three Bentall Centre",
  "industry": "Biotechnology",
  "address2": "595 Burrard Street Suite 1703",
  "previousClose": 1.65,
  "regularMarketOpen": 1.66,
  "twoHundredDayAverage": 1.692375,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 1.6699,
  "navPrice": null,
  "averageDailyVolume10Day": 9375,
  "totalAssets": null,
  "regularMarketPreviousClose": 1.65,
  "fiftyDayAverage": 1.692375,
  "trailingAnnualDividendRate": null,
  "open": 1.66,
  "averageVolume10days": 9375,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": null,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 1.66,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 7000,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 57883740,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 9375,
  "priceToSalesTrailing12Months": null,
  "dayLow": 1.66,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 7000,
  "fiftyTwoWeekHigh": 1.773,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 1.45,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 1.6699,
  "exchange": "PNK",
  "shortName": "NERVGEN PHARMA CORP",
  "longName": "NervGen Pharma Corp.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "NGENF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_577702483",
  "uuid": "c643fe7c-bc4e-3aef-b13f-5cf62f2bcc81",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 35116900,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.13783,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 30140814,
  "enterpriseValue": 58641668,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 1.66,
  "logo_url": "https://logo.clearbit.com/nervgen.com"
}